Delivery Order SPE2DB24D2205-SPE2DB24FDXAC

Award Date 7/17/24
Potential Completion Date 7/18/24
Potential Value $56K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $56,970.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a prescription medication, to support military healthcare programs. The contract is a Firm Fixed Price Delivery Order with a period of performance through February 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,542.83, is a Delivery Order for the pharmaceutical product XIFAXAN 550 MG TABLET 60S. The contract has an ultimate completion date of January 23, 2025 and is a Firm Fixed Price arrangement. The award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $15,822.04, is for the delivery of XIFAXAN 550 MG TABLET 60S, with a period of performance through November 25, 2024. This award is a Delivery Order under an existing Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,721.40, is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves...
This federal contract award, valued at $20,613.61, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,742.13 Firm Fixed Price Delivery Order contract is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a performance period through January 6, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,397.03 firm-fixed-price delivery order is for XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has a period of performance through June 6, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,540.33, is a Delivery Order for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The award has an ultimate completion date of December 19, 2023 and is a Firm Fixed Price contract. The contract is not designated with a set-aside requirement, indicating open competition....
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,952.81 fixed-price delivery order is for XIFAXAN 550 MG TABLET 60S, and has an ultimate completion date of November 13, 2023. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, running through November 2026,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,678.84, is a delivery order for the provision of XIFAXAN 550 mg tablets. The contract has an ultimate completion date of December 30, 2024 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB24FDXAC
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XIFAXAN 550 mg tablets. The award, valued at $56,319.43, is a firm fixed-price delivery order with a completion date of July 18, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition. The DLA is the funding agency for this contract, which aligns with their role in supporting military and veterans' healthcare needs through the procurement of essential medical commodities.

Generated 5/17/25, 9:42 AM